Krop I - Search Results

1

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update.

Krop I, Ismaila N, Andre F, Bast RC, Barlow W, Collyar DE, Hammond ME, Kuderer NM, Liu MC, Mennel RG, Van Poznak C, Wolff AC, Stearns V. Krop I, et al. J Clin Oncol. 2017 Aug 20;35(24):2838-2847. doi: 10.1200/JCO.2017.74.0472. Epub 2017 Jul 10. J Clin Oncol. 2017. PMID: 28692382 Free PMC article.

2

Diagnostic dilemmas in oncology. Case 3. Metastatic ovarian cancer simulating colon cancer.

Krop IE, Wieczorek TJ, Mayer RJ. Krop IE, et al. J Clin Oncol. 2000 Sep;18(17):3189-92. doi: 10.1200/JCO.2000.18.17.3189. J Clin Oncol. 2000. PMID: 10963649 No abstract available.

3

Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.

Guix M, Granja Nde M, Meszoely I, Adkins TB, Wieman BM, Frierson KE, Sanchez V, Sanders ME, Grau AM, Mayer IA, Pestano G, Shyr Y, Muthuswamy S, Calvo B, Krontiras H, Krop IE, Kelley MC, Arteaga CL. Guix M, et al. Among authors: krop ie. J Clin Oncol. 2008 Feb 20;26(6):897-906. doi: 10.1200/JCO.2007.13.5939. Epub 2008 Jan 7. J Clin Oncol. 2008. PMID: 18180460 Clinical Trial.

4

Epithelial and stromal cathepsin K and CXCL14 expression in breast tumor progression.

Kleer CG, Bloushtain-Qimron N, Chen YH, Carrasco D, Hu M, Yao J, Kraeft SK, Collins LC, Sabel MS, Argani P, Gelman R, Schnitt SJ, Krop IE, Polyak K. Kleer CG, et al. Clin Cancer Res. 2008 Sep 1;14(17):5357-67. doi: 10.1158/1078-0432.CCR-08-0732. Clin Cancer Res. 2008. PMID: 18765527 Free PMC article.

5

Mechanisms of trastuzumab resistance in breast cancer.

Tolaney SM, Krop IE. Tolaney SM, et al. Anticancer Agents Med Chem. 2009 Mar;9(3):348-55. doi: 10.2174/1871520610909030348. Anticancer Agents Med Chem. 2009. PMID: 19275526 Review.

6

Managing trastuzumab-resistant breast cancer.

Krop I. Krop I. Clin Adv Hematol Oncol. 2009 Feb;7(2):108-10. Clin Adv Hematol Oncol. 2009. PMID: 19367251 No abstract available.

7

Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology.

Peppercorn J, Shapira I, Collyar D, Deshields T, Lin N, Krop I, Grunwald H, Friedman P, Partridge AH, Schilsky RL, Bertagnolli MM. Peppercorn J, et al. Among authors: krop i. J Clin Oncol. 2010 May 20;28(15):2635-40. doi: 10.1200/JCO.2009.27.2443. Epub 2010 Apr 20. J Clin Oncol. 2010. PMID: 20406927 Free PMC article.

8

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.

Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, Girish S, Tibbitts J, Yi JH, Sliwkowski MX, Jacobson F, Lutzker SG, Burris HA. Krop IE, et al. J Clin Oncol. 2010 Jun 1;28(16):2698-704. doi: 10.1200/JCO.2009.26.2071. Epub 2010 Apr 26. J Clin Oncol. 2010. PMID: 20421541 Clinical Trial.

9

Advances in targeting SRC in the treatment of breast cancer and other solid malignancies.

Mayer EL, Krop IE. Mayer EL, et al. Clin Cancer Res. 2010 Jul 15;16(14):3526-32. doi: 10.1158/1078-0432.CCR-09-1834. Clin Cancer Res. 2010. PMID: 20634194 Review.

10

Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer.

Olson EM, Lin NU, DiPiro PJ, Najita JS, Krop IE, Winer EP, Burstein HJ. Olson EM, et al. Among authors: krop ie. Ann Oncol. 2012 Jan;23(1):93-97. doi: 10.1093/annonc/mdr061. Epub 2011 Apr 29. Ann Oncol. 2012. PMID: 21531783 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

243 results

Search Page

Filters